Literature DB >> 10439528

Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin.

T G Phan1, R C Wong, K Crotty, S Adelstein.   

Abstract

A 31-year-old man with the acquired immunodeficiency syndrome who developed toxic epidermal necrolysis (TEN) was successfully treated with intravenous immunoglobulin. He presented with a widespread, blistering skin rash, extensive mucosal ulceration, high-grade fever and pancytopaenia. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, was suspected as the culprit drug, although the patient had been taking this medication for 6 months. The patient also demonstrated an increased number of gamma/delta (gamma delta) T cells that decreased concomitantly with his clinical improvement. This correlation has not been described in TEN previously and may be of pathophysiological significance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10439528     DOI: 10.1046/j.1440-0960.1999.00347.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  4 in total

1.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 2.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

3.  Review of intravenous immunoglobulin in the treatment of stevens-johnson syndrome and toxic epidermal necrolysis.

Authors:  Saira B Momin
Journal:  J Clin Aesthet Dermatol       Date:  2009-02

4.  Severe antiretroviral therapy-induced toxic epidermal necrolysis in a child.

Authors:  Joseph M Norris; Laura H Stuttaford; Lyn F Dowds
Journal:  Case Rep Dermatol       Date:  2012-02-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.